Creative Biolabs is a leading service provider that focuses on discovery and development of in vitro diagnostic (IVD) antibodies with high specificity, high sensitivity for diagnosis, therapeutic monitoring, and guiding the use of targeted therapies. Based on our comprehensive platform and years of experience, professional experts from Creative Biolabs are confident in offering the best quality services of IVD antibody discovery against various markers of lung cancer.
General Introduction of a New Plasma Biomarker IDH1
Isocitrate dehydrogenase 1 (IDH1) is one of three isocitrate dehydrogenase isozymes, the other two being IDH2 and IDH3. IDH1 is a new plasma biomarker shown to be more sensitive in detecting non–small cell lung cancer (NSCLC), compared with currently used biomarkers like CEA, Cyfra21-1, and CA125. IDH1 is detected in the blood of lung cancer patients with 76% sensitivity and 77% specificity. By IHC analysis, IDH1 protein is located in the cytoplasm of tumor cells of SCC and AD. The expression of IDH1 in SCC patients is significantly higher in tumor tissues with 72.6% positive staining than paired normal lung tissues with only 8.2% positive staining as shown in Fig. 1 (A and B).
Fig.1 Immunohistochemical staining against IDH1 in tumors of both squamous cell carcinoma. (A) and adenocarcinoma (B) compared with corresponding normal lung tissues. (Tan, F., 2012)
Elevated Expression of CR-1 and Poor Prognosis in NSCLC
Effective biomarkers for the diagnosis of non–small cell lung cancer (NSCLC) are needed. Evidence shows that IDH1 is significantly increased in NSCLC tumors patients with other cancer types. Integrated analyses of plasma IDH1, CEA, Cyfra21-1, and CA125 provide a better panel of diagnostic tools for the rapid diagnosis of NSCLCs. This will enable the treatment of NSCLCs timely and effective. DH1 can only be used as an adjunct approach for diagnosis. The integrated results show that IDH1 could be used in the diagnosis of NSCLCs and is more effective than the existing blood biomarkers of lung adenocarcinoma.
Antibody-based IVD tools have been extensively used for disease screening and therapeutic monitoring. A series of immunoassays such as immunonephelometry and sandwich ELISA have been developed for these purposes. Through our role as a leading antibody development company, Creative Biolabs is proud to provide novel IDH1-specific antibody development services from scratch to commercial IVD kit (we can also start with available antibodies).
Please feel free to contact us for a detailed quote.
Reference
For Research Use Only.
